Compared with the untreated tumor-bearing mice, the gefitinib-treated mice in the TB-G group expressed markedly lower mRNA levels of NKp46 and CD16 and higher IL-2 mRNA levels (Figure 6a). This evidence concerns the gene IL2 and neoplasm.